"While CSR has been seen to be the preserve of the branded industry, there are many ways that generics firms of all sizes can immediately act more responsibly. These included fund-raising for causes that help increase access; donating surplus stock; taking part in co-ordinated industry-wide responses to emergencies; and helping to build good manufacturing practice (GMP) capacity in the developing world."
As you know, at Alvogen we believe it is our corporate social responsibility to advance health and improve lives across the globe and every year we support many worthy causes under the umbrella of our Better Planet global charity fund. These have included fund raising events to support UNICEF's immediate relief program for children in South Sudan and funds collected to enable UNICEF to set up health centers across the Sahel region, as well as donations to the Red Cross and resources to promote education for children in Madagascar and Sierra Leone, to mention but a few examples.
Alvogen's nomination for the CSR Initiative of the Year Award comes in the wake of other nominations, since the company is also up for awards in three categories in the annual Global Generics and Biosimilar Awards 2015, sponsored by trade publication, Generic Bulletin. Like last year, the awards will be given out during the CphI show in Madrid on 13 October 2015. As most of you will remember, Alvogen and Alvotech were nominated in 11 categories last year and scooped two awards: Company of the Year Americas and Business Development Initiative of the year.
Our CEO, Robert Wessman, will be interviewed in the next printed publication of Generics Bulletin published in the first week of October. This will be the biggest and most read publication of the year and distributed free at CphI. This year Alvogen's nominations include: Company of the Year (overall), Company of the Year (EMEA) and Leader of the Year (Robert Wessman).